Can you provide keytruda's initial fda approval date for cancer indications?

Keytruda (pembrolizumab) received its first FDA approval for a cancer indication on June 20, 2014. The drug was initially approved for the treatment of metastatic melanoma that had progressed after ipilimumab and for which tumor tissue was available. Subsequent approvals expanded Keytruda’s use to a variety of other solid tumors and hematologic malignancies.